The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access? On-Demand Webinar
This webinar will explain how pricing has evolved for the rare disease drug market and best practices for supporting value-based pricing.
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing Publication
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
How to Demonstrate Virtual Bioequivalence for Complex Dermal Generic Drugs On-Demand Webinar
This webinar will explain how Certara expanded its PBPK Simcyp Simulator to incorporate an extensive dermal model— MPML MechDermA, a multi-phase, multi-dimensional dermal absorption model.
Legal Notice Page
Legal Notice 1. Introduction and Acceptance of Terms of Use. Via its website, Certara, Inc. (“Certara”), together with its wholly-owned subsidiaries including Certara USA, Inc. (“Certara USA”), Certara UK Ltd. (“Simcyp”), Pinnacle 21 LLC (“P21”), Chemaxon Kft. (“Chemaxon”), and Synchrogenix...
